Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
Subscribe To Our Newsletter & Stay Updated
